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INTRODUCTION
The treatment of early stages of the knee joint osteoarthritis
continues to present challenges in orthopaedic practice. The
ideal therapy should target both the inflammatory and the
tissue degeneration processes in the joint building tissue,
the combination of which characterises the development of
osteoarthritis. Routinely per oral used nonsteroidal anti-
inflammatory drugs (NSAID) and corticosteroid injections
successfully reduce inflammation; however, an effect on the
degenerative process in joint structures, such as cartilage,
the synovial membrane and the metaphyseal bone has not
been demonstrated. Additionally, long-term use of NSAID
therapy is commonly associated with gastrointestinal, he-
patic, renal, and/or cardiac side effects amongst others, etc.
(McAlindon et al., 2014)
Alternatives include viscosupplementation, a treatment that
utilises hyaluronic acid (HA). It provides joint lubrication
and shock absorbency, and acts as a backbone for the
proteoglycans of the extracellular matrix (Kon et al., 2012).
However, the evidence gathered from clinical trials does not
clearly support any positive effects of HA on slowing down
the progression of OA, and the guidelines for the clinical
use of the HA are not recommended unanimously, advising
for a cautious employment of this treatment (Hunter, 2015;
van Tiel et al., 2016). The limitations of the NSAID,
corticosteroids and the HA have motivated further research
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The clinical effects on knee osteoarthritis (OA) symptoms and tissue structure were evaluated af-
ter bone marrow-derived mononuclear cell intraarticular injection. A group of 32 patients with 34
knee joints in stage II–III osteoarthritis were treated by intraarticular injection of mononuclear cell
suspension. Clinical results were obtained by KOOS (Knee Osteoarthritis Outcome Score) and
KSS (Knee Society Score) scores during a 12 months follow-up period. Radiological evaluation
was performed using magnetic resonance imaging. A comparison with a control group of 28 pa-
tients treated with routinely used three hyaluronic acid intra-articular injections was made. No ad-
verse effects were observed after the bone marrow derived mononuclear cells (BM-MNC)
injection. At the end point of the follow up all score results had improved, compared to those at to
the starting point. 65% of patients maintained minimal perceptible clinical improvement of the
score results. The Whole Organ Magnetic Resonance Imaging Score showed improvement from
44.31 to 42.93 points (p < 0.05) during a 6–7 month period. Comparing score results to the con-
trol group, a statistically significant (p < 0.05) improvement in the KOOS pain subscale score at
the 6 and 12 months was observed in the mononuclear cell group. BM-MNC injection leads to a
decrease of knee OA symptoms and slows changes in structure of the degenerative joint tissue.
Key words: knee osteoarthritis, mesenchymal stem cells, hyaluronic acid, bone marrow
mononuclear cells, regenerative therapy.
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into solutions that could provide clinical benefits of OA
treatment. Recently, new biological treatments have been
developed with platelet-rich plasma (PRP) (Filardo et al.,
2015b, a) and mesenchymal stem cells (MSCs), to address
cartilage lesions and the OA degeneration process. Stem
cells represent naive cells that differentiate to specific tissue
lineages during development. These cells reside within tis-
sue compartments with a purpose to replace cell populations
over the lifetime. In the 1970s, Freidenstein discovered that
cells extracted from red bone marrow in vitro demonstrated
properties of adherence, colony formation, and osteogenic
lineage differentiation (Friedenstein, 1976). Later in the
1990s, Caplan named these cells mesenchymal stem cells
(MSCs) and proposed that they would have a differentiation
capacity for all mesenchymal tissues.(Caplan, 1991). So far
this theory has not been sufficiently proven and the concept
of the bone marrow derived cells as ‘stem’ cells remains
open to debate. Later, Caplan revised the concept of
multipotent stem cells and proposed that pericytes, the cells
closely associated with capillaries and micro-vessels, are
the main source of multipotent stem cells (Caplan, 2008).
The International Society of Cell Therapy defined MSCs as
plastic-adherent, capable of trilineage differentiation and
possessing the cell surface antigens CD105, CD73, and
CD90 with a lack of CD45, CD34, CD14, CD11b, CD79á,
CD19, or HLA-DR. (Dominici et al., 2006) The attractive-
ness of the MSCs in cartilage repair can be found in their
immunomodulatory capacity and trophic factor production.
MSCs have immune properties to suppress immune cell
proliferation and cytokine release (Chen et al., 2013). De-
spite the theoretical controversies, clinical studies that ex-
amine the use of the MSCs in treating chondral injury and
OA, have demonstrated encouraging clinical outcomes, as
well as the magnetic resonsnce imaging (MRI)) and
histological findings, consistent with restoration of hyaline-
like cartilage (Gobbi et al., 2014; Nakamura et al., 2014;
Gobbi and Whyte, 2016). The renewal of joint building tis-
sue and slowing down of degenerative processes caused by
OA has been reported (Friedenstein et al., 1966; Caplan and
Dennis, 2006). A uniform evaluation of clinical benefit of
the BMSC-based therapy of larger patient groups is still
missing.
The primary aim of this study was to determine the clinical
effectiveness, and changes in pain and OA symptoms after a
single intra-articular injection of bone marrow derived
mononuclear cells (BM-MNC) on Kellgren Lawrence clas-
sification (K-L) grade II–III affected joints over a period of
12 months, in comparison with the clinical effectiveness of
a patient group treated with hyaluronic acid injections. The
secondary aims were to evaluate the joint building tissue
structural changes over a 12 months follow-up period using
X-ray and magnetic resonance imaging methods, and to ob-
serve the presence of adverse events associated with applied
therapy.
MATERIALS AND METHODS
The study employed a randomised controlled trail (RCT)
with evidence level II. The study was conducted in the Lat-
vian State Hospital for Traumatology and Orthopaedics and
Cell Transplantation Centre at Pauls Stradiòð Clinical Uni-
versity during 2012–2016.
The inclusion criteria were: degenerative osteoarthritis of
the knee, K-L grade II–III, at least 6 months of persisting
pain and some of OA symptoms. The exclusion criteria
were: age 75 years, oncologic diseases, severe kidney, lung
or liver function disorder, haematologic diseases including
anaemia and thrombocytopenia, first-type diabetes mellitus,
severe effusion, contracture or instability and axial deformi-
ties more than 10 degrees in the knee joint, septic arthritis
or skin disorders, use of corticosteroids and immunosup-
pressive agents, previous injection in target knee within two
months. Before the inclusion, the clinical history, physical
examination, routine laboratory tests, calibrated X-ray and
MRI were performed. The previous medical history of the
enrolled patients was carefully evaluated. The injection was
performed not prior to 1 month after the surgical interven-
tion in the same knee joint.
The clinical study protocol was approved by the State Cen-
tral Medical Ethics Committee. All patients provided in-
formed consents for the study according to the Helsinki
Declaration and all patients voluntarily agreed to participate
and signed informed consent forms.
Patients in the control group received in total three Na hya-
luronate (HA) intra-articular injections with an interval of
one week, starting at week 1 and finishing at week 3. A
GO-ON 25 mg/2.5 ml pre-filled syringe containing Na hya-
luronate 1% gel, average molecular weight 800–1500 kD,
was used.
Bone marrow harvesting and cell preparation. Cells used
in this study were extracted from the patient’s own red bone
marrow. Iliac crest puncture was performed under local an-
aesthesia. A total of up to 45 ml of bone marrow was aspi-
rated into heparin-treated syringes. The bone marrow aspi-
rate was shipped at room temperature to the central
cell-processing laboratory. The bone marrow aspirate was
processed according to Good Manufacturing Practice stan-
dard (GMP) requirements. The bone marrow mononuclear
cells (BM-MNCs) were isolated and enriched by density
gradient centrifugation by Ficoll-Paque Premium (GE
Healthcare Ltd.). Mononuclear cell fraction separation was
performed at 800 g for 25 min. The MNC fraction was
washed three times with 45 ml 0.9% NaCl containing 10
U/ml heparin and re-suspended in saline with 10 000 U/L
heparin. This isolation produced up to 5cc MNC suspen-
sion. During the gradient centrifugation, plasma factors, red
blood cells and platelets where removed. The cell suspen-
sion used for injection contained only the mononuclear cell
fraction and no other additional biological substances were
added.
Flow cytometry was used to determine the MNCs count and
cell viability in the cell material released for application.
Samples of the final product were taken and used for flow
cytometric analysis within 2 h after processing. Measure-
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ments with less than 50 000 events were excluded from the
cell count analysis.
Follow-up and BM-MNC injection procedure. Knee joint
puncture without using local anaesthesia was performed. To
be sure of correct needle placement in the joint cavity, 5 to
10 ml of saline was injected. In case of free drainage of the
saline by aspiration, correct placement in the knee joint cav-
ity was conducted. The mononuclear cell suspension injec-
tion into the knee joint was performed without changing the
needle position. After 1 hour of bed rest, patients were re-
leased home. No restrictions on further activities were
given. The short term use of pain reliever drugs during the
evaluation period of 12 months was accepted. The patients
maintained previous habit of SYSODOA drug use and
physical activity level. Regarding the physical activity at
enrolment, patients were given recommendations to avoid
excessive physical activity and sport exercises exceeding
their normal everyday activities and habits. Evaluations
were made on visits of patients at 1, 3, 6 and 12 months.
Clinical assessment. The clinical assessment was based on
outpatient visits. Pain, changes in OA symptoms and knee
joint function after physical examinations were assessed us-
ing the Knee Society Score (KSS). This scoring system is
the version of the knee score modified by Dr. John Insall in
1993. The scoring system combines a relatively objective
Knee Score that is based on clinical parameters and a Func-
tional Score based on how the patient perceives his knee
functions during specific activities. The maximum Knee
Score is 100 points and the maximum Functional Score is
100 points (Insall et al., 1989). At the same time, patients
completed the Knee Osteoarthritis Outcome Score (KOOS)
test. KOOS consists of five subscales: pain, symptoms, and
activities of daily living (ADL), sport and the recreation
function (Sport/Rec), and the knee-related quality of life
(QOL). A KOOS score of 100 indicates no symptoms and 0
indicates extreme symptoms (Roos et al., 1998). Scoring
was done on the day of the procedure and 1, 3, 6 and 12
months after BM MNC injection.
Radiological assessment. Weight-bearing anteroposterior
and lateral semi flexed radiographs were obtained before
the cell injection procedure and 12 months later. Radio-
graphs were scored according to the K–L classification. Pa-
tients with grade 2 and 3 were enrolled for the study.
The MRI was performed only on the study group prior to
and 6 to 7 months after BM MNC injection. The MRI ex-
aminations were performed with a 1.5T scanner, using a
dedicated knee coil. All patients were placed in the supine
position. The MRI protocol included PD Fat Sat sequence
on the sagittal, coronal, and axial planes, and PD FSE on
the sagittal and coronal planes,
All X-rays and MRI images were evaluated by a musculo-
skeletal radiologist from another institution. The examiner
was blinded to all clinical data. The MRI evaluation was
performed using the semi-quantitative whole organ MRI
scoring (WORMS) method. The WORMS score allows to
analyse 14 different features: articular cartilage integrity,
subarticular bone marrow abnormality, subarticular cysts,
subarticular bone attrition, marginal osteophytes, medial
and lateral meniscal integrity, anterior and posterior cruciate
ligament integrity, medial and lateral collateral ligament in-
tegrity, synovitis/effusion, intraarticular loose bodies, and
periarticular cysts/bursitis. These features were evaluated
and scored (Table 1) in 15 different regions subdivided by
anatomical landmarks in the fully extended knee (Peterfy et
al., 2004).
Statistical analysis. All data were analysed using IBM
SPSS 22.0 software. Firstly, data were analysed for normal-
ity using skewness and kurtosis as well as a histogram and a
Q-Q plot. If the data were normally distributed, then a
paired or independent Student`s t-test was performed.
Paired t-tests were made to compare KSS, OKS, and KOOS
subscales between the baseline and follow-up times within
each group. A p-value 0.05 was considered as statistically
significant. The Levene’s test was used to evaluate homoge-
neity between the two study groups. An independent Stu-
dent’s t-test was used to compare the BMSC and HA
groups. If data were not normally distributed, then the
Mann–Whitney U test was used.
RESULTS
Seventy-two KL stage II–III knee OA patients were
screened, of whom 56 were included in the study according
inclusion and exclusion criteria (Fig.1). The patients were
randomly divided into two groups: a bone marrow-derived
mononuclear cells (BM-MNC) group and a hyaluronic acid
(HA) as a control group. The patient randomisation process
is presented in Figure 1.
After the comparison of clinical results between both
groups, the study group was extended to 32 patients accord-
ing to the same inclusion and exclusion criteria. The mean
age of the new study group was 53.96 ± SD14.15 years,
T a b l e 1
MAXIMUM SCORES ATTAINABLE WITH WORMS
MFTJ LFTJ PFJ S Region Total
Cartilage 30 30 24 84
Marrow abnormality 15 15 12 3 45
Bone cysts 15 15 12 3 45
Bone attrition 15 15 12 42
Osteophytes 35 35 28 98
Compartment total 110 110 88




WORMS, Whole-organ Magnetic Resonance Imaging Score; MFTJ, me-
dial tibiofemoral joint compartment; LFTJ, lateral tibiofemoral joint com-
partment; PFJ, patellofemoral joint compartment; S Region, subspinous
non-articulating joint compartment
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male 16, female 16. Two of 32 patients received MNC in-
jections in both knee joints. Based on previous medical his-
tory, total knee arthroplasty on the contra lateral knee joint
was performed on ten patients, and total hip replacement in
one patient case. Arthroscopy with meniscus resection on
the same knee joint was performed on 11 patients and in
one case an ACL replacement had been previously done.
The two youngest patients of the cohort had a previous his-
tory of patellar dislocations.
No adverse effects after the BM-MNC injection were ob-
served. The patients reported the procedure of the iliac crest
puncture as painless and no complications in donor sites
were observed. The knee joint pain and swelling caused by
the puncture and the BM-MNC injection declined during
the first 24 hours in the majority of patients. No additional
treatment was applied. A positive response was observed in
patients for 97% of knees after the BM-MNC injection. At
the end point of the follow up all subscale results had im-
proved, compared to those at the starting point. The KOOS
total score improved by + 15.3 points, the symptoms
subscale by + 9.3, the pain subscale by + 20.5 points, the
activity and the daily living subscale by + 18.4, the sports
subscale by + 18.5 and the quality of life subscale by + 23.9
points. Table 2 KOOS score results during the follow-up
period.
A statistical analysis of the KOOS score results in all
subscales between the starting point and the follow-up times
demonstrated statistically significant improvement (p <
0.05) on all subscales, except on symptoms subscale at time
12 months and the sport subscale at 1 month after the BM
MNC injection.
During the first months after the BM-MNC injection, the
biggest improvement was observed in the pain, and activity
of the daily living subscales; however, the results in the
sport and the quality of life subscales improved more pro-
gressively during the 12-month period.
Fig. 1. The participation status of the study sub-
jects phase I.
T a b l e 2
KOOS SCORE RESULTS DURING THE FOLLOW-UP PERIOD
Time point Symptom Pain Activity of daily
living
Sport Quality of life Total
beginning Mean±SD 60.8±20,1 60.2±19.0 66.9±20.3 43.7±24.8 35.1±20.0 61.6±15.0
1st month Mean±SD 77.0±16.6 84.3±10.1 87.9±10.3 57.4±18.3 52.4±22.7 71.3±15.1
3rd month Mean±SD 75.5±18.3 80.1±16.7 83.6±16.2 68.7±22.4 57.3±23.4 78.3±16.0
6th month Mean±SD 72.2±19.8 81.5±16.2 84.7±15.2 67.3±19.8 50.9±22.7 78.7±12.2
12th month Mean±SD 70.1±19.7 80.7±16.8 85.0±14.1 65.2±18.7 59.0±18.9 76.9±13.3
KOOS, Knee Osteoarthritis Outcome Score
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The clinically relevant changes of symptoms or minimal
perceptible clinical improvement measured with the KOOS
score begin at a threshold of 8–10 point difference (Roos
and Lohmander, 2003).
After 12 months, 65% of patients still showed improvement
of more than 10 points of the KOOS total score. After 6
months, 78.26% of patients showed improvement in the
pain subscale by more than 10 points, compared to 66.67%
of patients after 12 months. However the proportion of pa-
tients with more than 10-point improvement of the quality
of life subscale increased from 65.22% after 6 months to
75% after 12 months (Fig. 2).
Figure 2 shows the proportion of patients that reached a
10-point improvement level during the follow up period.
The OA clinical signs measured with KSS demonstrated
improvement in both the knee score and the function score
subscales (Table 3). After 12 months, the KSS knee score
showed + 21.45 and the function subscale + 27.08 points
improvement (Table 3).
The KSS knee score subscale demonstrated a similar pattern
as compared to the KOOS score. The KSS knee score that
evaluated pain and symptoms demonstrated improvement
particularly during the first month whereas the functions
score improved more progressively.
Results of radiological investigation. The X-rays showed
no signs of further development of OA and no changes in
the K-L grade 12 months after the BM-MNC injection.
Non-expected changes in bone structure or any periosteal
reaction were not evident.
MRI was performed on 30 of 34 study group patients. Un-
fortunately, four patients refused to undergo the final MRI
due to different reasons. The MRI was evaluated using the
WORMS score. The mean score before the injection was
44.31 points and after 6 months, a significant (p < 0.05) im-
provement to 42.93 points was observed. We found changes
on three of WORMS score features: articular cartilage,
subarticular bone marrow and synovitis (Table 4). In all
other WORMS score features changes during the follow up
period was not observed.
Further analysis of the WORMS bone marrow abnormali-
ties section demonstrated a decrease of bone marrow oe-
dema in 57.14% of patients after 6 months, where 28.57%
did not change, but in 14.29% worsening was observed.
Cartilage changes on the MRI after 6 months improved in
37.93%, no change was observed in 55.17% and further de-
Fig. 2. Minimal perceptible clinical improvement
of 10 points by KOOS score
T a b l e 3
KSS SCORE RESULTS DURING THE FOLLOW UP PERIOD
KSS score results KSS knee score p KSS Function p
beginning Mean±SD 60.25±18.52% 62.55±22.81%
1st month Mean±SD 80.81±13.37% 0.00006 79.91±19.40% 0.00019
3rd month Mean±SD 80.41±15,84% 0.00024 87.44±16.65% 0.00002
6th month Mean±SD 80.39±18.24% 0.00017 87.68±14.75% 0.0001
12th month Mean±SD 81.70±18.56% 0.0024 89.63±14.27% 0.00014
KSS, Knee Society Score
T a b l e 4
WORMS SUBSCALE RESULTS
Cartilage results Bone marrow
abnormality results
Synovitis results
Before 17.69±14.61 1.58±2.579 1.24±0.7
After 17.13±14.71 0.97±1.94 0.67±0.86
p < 0.05
WORMS, Whole-organ Magnetic Resonance Imaging Score
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generation was present in 6.90% of cases. The MRI changes
related to the synovitis improved in 63.16% of cases, no dif-
ference in 31.58% and increased in 5.26% of cases (Fig. 3).
In a clinical case of a 62-year-old woman with K-L stage III
OA, MR scans (Fig. 4a; b) demonstrated patellar cartilage
defect according to WORMS 3. MR scans 7 months after
BM-MNC injection are shown in Fig. 4 c; d Cartilage resto-
ration to WORMS 0 was observed. The KOOS total after 12
months improved by + 28 p.
In a clinical case of a 56-year-old woman with K-L stage III
OA, a MR scan (Fig. 4e) demonstrated BMO of tibia ac-
cording to WORMS 3 and synovitis 3. MR scans 6 months
after BM-MNC injection are shown in Fig. 4f. Bone mar-
row edema reduced to WORMS 0 and synovitis to
WORMS 1. The KOOS total after 12 months improved by
+ 25 p.
Cell material analysis. Before the injection, flow cyto-
metry tests were applied to each extracted mononuclear cell
sample. The mononuclear, the CD34+ population count
and cell viability were determined. From 34 cell processing
runs, 24 flow cytometry tests were analysed, and 10 were
excluded according to the protocol, as the measurement did
not reach 50 000 events. The average final yield of cell ex-
traction was 45.56·106 ± 34.94·106 MNC containing
1.04·106 ± 1.61·106 CD34+ cells. The cell viability was de-
termined prior to the cell extraction process in the red bone
marrow and after the final cell preparation. The average cell
viability in the red bone marrow was 74.36 ± 9.85%, but af-
ter the preparation processes the viability increased to 79.75
±11.28%.
No positive correlation between the used cell quantity and
the OA clinical signs of improvement was found.
The comparison of BM MNC and HA groups. The clini-
cal results of randomised 28 patients of the mononuclear
cell and hyaluronic acid groups were compared based on the
score results, 12 months after the first injection (Table 5).
All results in the BM MNC group were superior to the HA
group except on the KOOS symptom subscale.
Fig. 3. Cartilage changes on the MRI after 6 months.
Fig. 4. MR scans of a 62-year-old woman with
K-L stage III OA: a, before bone marrow derived
mononuclear cells (BM MNC) injection, cartilage
defect Whole-organ Magnetic Resonance Imaging
Score (WORMS) 3 on patella and femur lateral
surface; b, before BM MNC injection, cartilage
defect WORMS 3 on patella and femur medial
surface; c, seven months after BM MNC injec-
tion, cartilage restoration to WORMS 0; d, seven
months BM MNC injection, cartilage restoration
to WORMS 1 on medial patella surface and
WORMS 0 to medial femur surface; e, before BM
MNC injection, BMO WORMS 3 and synovitis
3; f, six months after BM MNC injection, BMO
WORMS 0 and synovitis WORMS1
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The bigest difference between the BM-MNC and the HA
groups was found on the KOOS pain subscale. The
BM-MNC group showed significant (p < 0.05) superiority
over the HA group, 6 and 12 months after injection (Fig. 5).
In all other score subscales the score result differences
lacked statistical significance (Fig. 5).
DISCUSSION
Clinical studies about the use of the BMSC in the treatment
of isolated cartilage lesions and the OA patients have re-
ported a clinical benefit in most of the studies, regardless of
the cell source, indication, or the administration method,
with better results in patient groups of younger age, a lower
BMI, a smaller lesion size, and earlier stages of OA. (Gupta
et al., 2012; Jo et al., 2014). No major adverse events,
strictly related to the treatment, have been reported (Filardo
et al., 2016).
Our results clearly demonstrate pain relief in the majority of
cases without any serious side effects. Stiffness and other
OA symptoms had not changed significantly. However, cor-
relation of improvement with age or OA K-L stage was not
evident in our patient group. Some studies demonstrated de-
crease of both knee pain and functions improvement using
bone marrow aspirate concentrate (BMAC) injection, pure
and augmented with PRP and adipose tissue in the knee OA
treatment (Centeno et al., 2014; Kim et al., 2014). How-
ever, more adverse effects like knee pain and swelling in the
BMAC and the BMAC combined with adipose tissue
groups were reported. In our patient group treated with the
BM MNC, adverse effects were not observed. We applied
the autologous bone marrow derived mononuclear cell frac-
tion containing a variety of different progenitor cell popula-
tions and an enriched MSC cell population. The bone mar-
row aspirate was processed in order to isolate mononuclear
cells and reduce contamination with red blood cells and
erythrocyte lysate. We assume that purification of the cell
solution is the reason why the adverse effects like swelling
and pain after the cell injection were not observed.
The cell yields and correlation to clinical effects are active
topics for discussion in all fields using the MSCs as a thera-
peutic agent. There is no clear answer so far. We observed a
wide range of cell yields (8.3 × 106 to 158.79 × 106). The
extracted mononuclear cell yield might be dependent on the
patient’s individual condition or the bone marrow acquisi-
tion and the cell processing quality. A previous study of the
BM-MNC processing efficacy found a similar variety of
mononuclear cell quantity (Jakobsons, 2013). The correla-
tion between the used mononuclear cell quantity and the
clinical improvement was calculated. Surprisingly no corre-
lation during 12 months was evident. A larger sample group
and a wider range between the used cell quantities could be
helpful to determine the optimal cell dosage patterns to
achieve the best clinical results. Comparing the clinical
T a b l e 5
SUBSCALE MEAN VALUE CHANGES BEFORE TO 12 MONTHS
AFTER THERAPY
Score subscales BM MNC group HA group
KOOS Symptoms 5.07 12.62*
KOOS Pain 25.44* 11.37*
KOOS Activity of daily living 21.36* 19.09*
KOOS Sport 19.00 5.97
KOOS Quality of life 28.83* 18.90*
KOOS Total 18.25* 12.59*
KSS Knee score 25.42* 10.73*
KSS Function 38.32* 17.5*
*p < 0.05
KOOS, knee osteoarthritis outcome score; BM MNC, bone marrow derived
mononuclear cells; HA, hyaluronic acid
Fig. 5. Knee osteoarthritis outcome score pain results com-
parison between BM-MNC and hyaluronic acid groups.
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effect measured with the KOOS score, the obtained im-
provement levels were similar to those reported previously
(Oliver et al., 2015). Approximately 10-point higher im-
provement levels were reported by Kim et al (2014). Both
teams used BMAC and lipoaspirate combination injected in
the OA affected knee joints (Oliver et al., 2015).
The assessment of scores of our patient group showed sig-
nificant reduction of pain starting with the first month post
procedure and lasting during the 12 month follow-up peri-
od. A maximum of beneficial effects such as pain, OA
symptoms, the activity of daily living, were reached at the
first month post procedure and continued at the same level
or slightly decreased during the 12 months of the follow up
period. Despite that, the quality of life improved continu-
ously and reached a maximum at month 12. The highest im-
provement was regarding knee pain. The least improvement
was observed in other OA symptoms like stiffness or crepi-
tation in the joint.
In a study using adipose derived cultured MSCs on knee
OA patients, MRI using the WORMS score significantly
improved from 60.0 points to 48.3 points (p < 0.001), and a
particularly notable change was observed in the cartilage
whole-organ MRI score, which improved from 28.3 points
to 21.7 points (p < 0.001) (Koh et al., 2013).
Our MRI findings also demonstrated an improvement of
score and a significant reduction of synovial effusion and
bone marrow oedema. Cartilage surface restoration was ob-
served in some individuals, but was not clearly evident in
the majority of cases. Bone marrow oedema usually is asso-
ciated with pain and activity of degenerative processes (Lee
et al., 2015). The loss of bone marrow integrity will com-
promise repair and regeneration and foster degeneration in
the joint cartilage. However a natural history of OA signs
detected on MRI could be taken in account. Lack of MRI
investigation of the control group requires us to be careful
to draw conclusions about the regenerative effect of the ap-
plied therapy. After assessing all findings, we can conclude
that the slowdowns of degenerative changes in some indi-
viduals after the BM MNC injection were evident.
Limitations. The placebo effect might play a role in the pa-
tients’ subjective self-scoring process, as we did not use a
blinded study. Some of the differences measured with
scores were not statistically significant because of high vari-
ability of results. There was no control group for evaluation
of the MRI results. Therefore, conclusions about tissue
structural changes cannot be presented with the highest
level of evidence strength. A larger sample size and a longer
follow-up period will be necessary to improve reliability of
the data and will be helpful to determine correlations of the
factors considered on outcome.
CONCLUSIONS
Intra-articular injection of BM MNC is a safe manipulation
with no side effects over a 12-month period.
A single dose injection of BM MNC reduces knee stage
II–III osteoarthritis symptoms and might decrease degenera-
tive changes in the joint tissue.
Mononuclear cells in knee osteoarthritis treatment is charac-
terised by better pain relief in the long-term period, compar-
ing to hyaluronic acid treatment.
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JAUNAS IESPÇJAS CEÏA LOCÎTAVAS OSTEOARTRÎTA ÂRSTÇÐANÂ, IZMANTOJOT AUTOLOGAS SARKANO KAULA
SMADZEÒU MONONUKLEÂRÂS ÐÛNAS
Pçtîjumâ izvçrtçtas ceïa locîtavas osteoartrîta klînisko simptomu un audu struktûru izmaiòas pçc ârstçðanas ar sarkano kaula smadzeòu
mononukleâro ðûnu intrartikulâru injekciju. Ceïa locîtavas II–III pakâpes osteoartrîta 32 pacientu grupai 34 ceïa locîtavâs tika ievadîta
mononukleâro ðûnu suspensija (MNÐ). Klîniskie rezultâti 12 mçneðu apsekoðanas periodâ tika izvçrtçti pçc Ceïa osteoartrîta iznâkuma un
Ceïa apvienîbas novçrtçjuma skalâm. Locîtavas audu struktûras izmaiòu novçrtçjumam tika izmantotas digitâlâs rentgenogrammas un
magnçtiskâs rezonanses metodes. Tika veikts klînisko rezultâtu salîdzinâjums ar 28 kontroles grupas pacientiem kas tika ârstçti ar jau
iepriekð praksç lietoto metodi — 3 hialuronskâbes (HA) injekcijas ar nedçïas starplaiku. Salîdzinot abas grupas, statistiski nozîmîgas (p <
0,05) atðíirîbas tika novçrotas KOOS skalas sâpju sadaïâ, kâ arî vairumâ no skalu apakðsadaïâm tika konstatçts MNÐ grupas pârâkums
osteoartrîta simptomu mazinâðanâ. Klîniski nozîmîgas blaknes abâs grupâs netika reìistrçtas. Pçc MNÐ ievadîðanas minimâli klîniski
nozîmîgais uzlabojums saglabâjâs 12 mçneðus 65% pacientu no MNÐ grupas. Magnçtiskâs rezonanses izmeklçjumos, 6 lîdz 7 mçneðus pçc
injekcijas izvçrtçjot pçc Visa orgâna magnçtiskâs rezonanses izmeklçjuma punktu skalas, tika konstatçtas izmaiòas no 44,31 uz 42,93 (p <
0,05), kas norâda uz locîtavas struktûru deìeneratîvo izmaiòu mazinâðanos. Mononukleâro ðûnu terapija 12 mçneðu periodâ ievçrojami
samazina osteoartrîta simptomus ceïa locîtavâ un palçnina audu deìeneratîvo izmaiòu veidoðanos.
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